AtriCure gets 510(k) clearance for AtriClip device

Shares of West Chester, OH-based AtriCure soared on news that the FDA approved the company's AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System, a device which blocks blood clots during heart procedures. AtriClip could bring in up to $300 million a year for the company. Story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.